IDEAYA Biosciences (IDYA) Receivables (2020 - 2024)

IDEAYA Biosciences has disclosed Receivables across 5 years of filings, most recently posting $3000.0 for Q4 2024.

• Receivables for Q4 2024 came in at $3000.0, down 83.33% year-over-year; the trailing twelve-month figure through Dec 2024 was $3000.0 (down 83.33% YoY), and the FY2024 annual result was $3000.0, down 83.33% from the prior year.
• Receivables came in at $3000.0 for Q4 2024 at IDEAYA Biosciences, down from $20000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $6.7 million in Q3 2023 to a low of $1000.0 in Q2 2024.
• The 5-year median for Receivables is $468000.0 (2023), against an average of $1.2 million.
• Across the five-year window, Receivables soared 238.8% in 2022 and plunged 99.7% in 2024, its largest moves.
• IDEAYA Biosciences' Receivables stood at $1.9 million in 2020, then sank by 41.24% to $1.1 million in 2021, then plunged by 80.87% to $211000.0 in 2022, then slumped by 91.47% to $18000.0 in 2023, then plunged by 83.33% to $3000.0 in 2024.
• The last three Receivables figures came in at $3000.0 (Q4 2024), $20000.0 (Q3 2024), and $1000.0 (Q2 2024), per Business Quant data.